Physician profile
Linda R Arous
NPI 1700043320
$3,462.64
in general payments reported to CMS, 2019-2025
18 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $66.28 · 2023: $725 · 2024: $1,090 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.38 | 2023-2025 | Wegovy, Ozempic |
| Gilead Sciences, INC. | $510.72 | 2023-2025 | Epclusa, Biktarvy |
| Glaxosmithkline, LLC. | $356.55 | 2023-2025 | Arexvy, Bexsero, Penmenvy |
| Lilly USA, LLC | $302.31 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $258.34 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.78 | 2021-2023 | Jardiance |
| Alkermes, INC. | $228.85 | 2023-2025 | Vivitrol, Vivitrol |
| Viiv Healthcare Company | $213.01 | 2022-2025 | Apretude |
| Amgen INC. | $182.67 | 2024-2025 | Repatha, Otezla, Repatha |
| Regeneron Pharmaceuticals, INC. | $129.94 | 2025 | Eylea Hd, Eylea |
| Dexcom, INC. | $110.97 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $100.00 | 2021 | |
| Exact Sciences Corporation | $80.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $53.01 | 2024-2025 | |
| Dynavax Technologies Corporation | $43.05 | 2022-2025 | Heplisav-B |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.57 | 2025 | |
| Currax Pharmaceuticals LLC | $16.05 | 2023 | Onzetra Xsail, Contrave |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Arous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.